Cannabicyclol (CBL) is a little-studied phytocannabinoid that occurs naturally in the cannabis plant. It has been investigated along with several other cannabinoids for its potential to inhibit production of prostaglandins (hormones that control smooth muscle contractions), but it was found to have the lowest biological activity of all tested compounds.
CBL itself differs from THC in that it contains no double bond within its molecule. Lacking a double bond entirely, CBL is not considered to have psychoactive potential, and it is not known if it has an affinity with the cannabinoid receptors.
What do we know about Cannabicyclol (CBL)
CBL is known to occur as a degradation product of cannabichromene (CBC). CBL has been found in samples of Pakistani hashish stored up to four years. All of the samples that contained CBL also contained CBC in higher concentrations. However, levels of both CBC and CBL were very low compared to the major constituents, THC, CBD, and CBN.
Very little is known about the medical potential of CBL(Cannabicyclol). It is clear that more research into CBL is necessary.